BioCentury
ARTICLE | Company News

Galmed, OWL aim to develop NASH diagnostic

July 9, 2015 12:42 AM UTC

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) partnered with One Way Liver Genomics S.L. (Derio, Spain) to develop a non-invasive, blood-based companion diagnostic for Aramchol arachidyl amino cholanoic acid to treat non-alcoholic steatohepatitis (NASH).

Galmed is conducting the Phase IIb ARREST trial of the synthetic conjugate of cholic acid and arachidic acid to treat NASH. The partners hope to develop a companion diagnostic that would replace liver biopsies and assist in patient selection for a planned Phase III study of Aramchol. ...